Mahanine mediated therapeutic inhibition of estrogen receptor-α and CDK4/6 expression, decipher the chemoprevention-signaling cascade in preclinical model of breast cancer

被引:3
|
作者
Samanta, Suman Kumar [1 ,2 ]
Choudhury, Paramita [2 ,3 ]
Kandimalla, Raghuram [2 ,4 ,5 ]
Aqil, Farrukh [4 ,6 ]
Moholkar, Disha N. [4 ,5 ]
Gupta, Ramesh C. [4 ,5 ]
Das, Momita [2 ]
Gogoi, Bhaskarjyoti [7 ]
Gogoi, Neelutpal [8 ]
Sarma, Partha Pratim [2 ]
Devi, Rajlakshmi [2 ]
Talukdar, Narayan C. [1 ]
机构
[1] Assam Down Town Univ, Fac Sci, Gauhati 781026, Assam, India
[2] Inst Adv Study Sci & Technol, Life Sci Div, Tradit & Modern Drug Discovery & Dis Diag Lab, Gauhati 781035, Assam, India
[3] Gauhati Univ, Dept Zool, Gauhati 781014, Assam, India
[4] Univ Louisville, Brown Canc Ctr, Louisville, KY 40202 USA
[5] Univ Louisville, Dept Pharmacol & Toxicol, Louisville, KY 40202 USA
[6] Univ Louisville, Dept Med, Louisville, KY 40202 USA
[7] Assam Royal Global Univ, Dept Biotechnol, Gauhati 781035, Assam, India
[8] Dibrugarh Univ, Dept Pharmaceut Sci, Dibrugarh 786004, Assam, India
关键词
Murraya koenigii; Mahanine; Breast cancer; Chemoprevention; ER alpha antagonist; CDK4/6; inhibitor; LEPTIN; RESISTANCE; GROWTH; CELLS; RNA;
D O I
10.1016/j.jep.2023.117235
中图分类号
Q94 [植物学];
学科分类号
071001 ;
摘要
Ethnopharmacological relevance: Mahanine (MH), a naturally occurring carbazole alkaloid, isolated from Ayurvedic medicinal plant Murraya koenigii (L.) Spreng, has been shown to have various pharmacological properties, including its inhibitory activity against different breast cancers (BC) subtypes.Aim of the study: While MH triggers apoptosis in BC cells regardless of subtype, the specific mechanism of MH action is not fully understood. In this study, we show the effect of MH in preventing BC progression by inducing apoptosis in relation to estrogen receptor-alpha (ER alpha) and cell cycle regulatory proteins.Materials and methods: To assess the pharmacological activity in various in vitro and in vivo tests, isolated and pure MH was used. To conclude the study, cutting edged molecular biology techniques including Western blot analysis, enzyme-linked immunosorbent assay (ELISA), molecular simulation study, and other related software analysis were employed.Results: MH demonstrated dose dependent cell viability against drug sensitive (MCF-7 and MDA-MB-231) and paclitaxel resistant (MCF-7TR and MDA-MB-231TR) BC cells. MH also exhibited synergistic activity with tamoxifen (TAM) against estrogen receptor positive (ER+) BC cells by inhibiting ER alpha expression in MCF-7 cells and N-Methyl-N-nitrosourea (MNU)-induced mammary tumor in a dose-dependent manner while having no effect on vinculin expression. In addition, MH inhibited cell cycle regulatory genes namely CDK1/CDK4/CDK6/ CDC25A and neo-angiogenesis through downregulation of CD31/PECAMs in MCF-7, MDA-MB-231 cells and mammary tumors from MNU-induced rats. MH therapy has been shown to be significantly able to lower the serum leptin level and to be beneficial against the initiation of tumor development in SD rats for up to 12 weeks. Molecular modeling study revealed that MH has antagonized the effectiveness of several types of estrogen those bind to the ER alpha and has comparable binding efficacy to TAM.
引用
收藏
页数:12
相关论文
共 50 条
  • [1] Mechanisms of therapeutic CDK4/6 inhibition in breast cancer
    Scott, Susan Combs
    Lee, Sarah S.
    Abraham, Jame
    SEMINARS IN ONCOLOGY, 2017, 44 (06) : 385 - 394
  • [2] STAT3 as a therapeutic target in estrogen receptor positive breast cancer patients refractory to CDK4/6 inhibition
    Kettner, Nicole M.
    Bui, Tuyen
    Ha, Min Jin
    Eckols, T. Kris
    Tweardy, David J.
    Meric-Bernstam, Funda
    Hunt, Kelly K.
    Tripathy, Debu
    Keyomarsi, Khandan
    CANCER RESEARCH, 2020, 80 (04)
  • [3] Early Adaptation and Acquired Resistance to CDK4/6 Inhibition in Estrogen Receptor-Positive Breast Cancer
    Herrera-Abreu, Maria Teresa
    Palafox, Marta
    Asghar, Uzma
    Rivas, Martin A.
    Cutts, Rosalind J.
    Garcia-Murillas, Isaac
    Pearson, Alex
    Guzman, Marta
    Rodriguez, Olga
    Grueso, Judit
    Bellet, Meritxell
    Cortes, Javier
    Elliott, Richard
    Pancholi, Sunil
    Baselga, Jose
    Dowsett, Mitch
    Martin, Lesley-Ann
    Turner, Nicholas C.
    Serra, Violeta
    CANCER RESEARCH, 2016, 76 (08) : 2301 - 2313
  • [4] Resistance to CDK4/6 Inhibitors in Estrogen Receptor-Positive Breast Cancer
    Scheidemann, Erin R.
    Shajahan-Haq, Ayesha N.
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2021, 22 (22)
  • [5] Therapeutic CDK4/6 inhibition in breast cancer: key mechanisms of response and failure
    J L Dean
    C Thangavel
    A K McClendon
    C A Reed
    E S Knudsen
    Oncogene, 2010, 29 : 4018 - 4032
  • [6] Therapeutic CDK4/6 inhibition in breast cancer: key mechanisms of response and failure
    Dean, J. L.
    Thangavel, C.
    McClendon, A. K.
    Reed, C. A.
    Knudsen, E. S.
    ONCOGENE, 2010, 29 (28) : 4018 - 4032
  • [7] Overcoming Therapeutic Resistance of Triple Positive Breast Cancer with CDK4/6 Inhibition
    Schedin, Troy B.
    Borges, Virginia F.
    Shagisultanova, Elena
    INTERNATIONAL JOURNAL OF BREAST CANCER, 2018, 2018
  • [8] CDK4/6 Inhibition as a therapeutic strategy in breast cancer: palbociclib, ribociclib, and abemaciclib
    Laderian, Bahar
    Fojo, Tito
    SEMINARS IN ONCOLOGY, 2017, 44 (06) : 395 - 403
  • [9] CDK4/6 inhibitor resistance in estrogen receptor positive breast cancer, a 2023 perspective
    Zhou, Fiona H.
    Downton, Teesha
    Freelander, Allegra
    Hurwitz, Joshua
    Caldon, C. Elizabeth
    Lim, Elgene
    FRONTIERS IN CELL AND DEVELOPMENTAL BIOLOGY, 2023, 11
  • [10] CDK4/6 inhibitor-mediatated radiosensitization of estrogen receptor positive breast cancer
    Pesch, Andrea M.
    Hirsh, Nicole
    Chandler, Benjamin C.
    Michmerhuizen, Anna R.
    Ritter, Cassandra L.
    Androsiglio, Marlie
    Wilder-Romans, Kari
    Liu, Meilan
    Gersch, Christina L.
    Larios, Jose M.
    Rae, James M.
    Speers, Corey W.
    CANCER RESEARCH, 2020, 80 (16)